Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
作者： Jose Lutzky , Juergen Bauer , Boris C. Bastian
DOI: 10.1111/J.1755-148X.2008.00475.X
关键词: Point mutation 、 Cancer research 、 Glutamic acid 、 Mucosal melanoma 、 Imatinib 、 Medicine 、 Targeted therapy 、 Melanoma 、 Proto-Oncogene Proteins c-kit 、 Intestinal mucosa
摘要:
sci-hub.se 参考文章(10)
Yale D. Podnos, Ni-Chun Tsai, David Smith, Joshua D.I. Ellenhorn, Factors affecting survival in patients with anal melanoma. American Surgeon. ,vol. 72, pp. 917- 920 ,(2006) , 10.1177/000313480607201017
O. Eton, L. Billings, K. Kim, V. Prieto, D. Davis, M. L. Frazier, A. H. Diwan, E. McGary, N. Papadopoulos, A. Y. Bedikian, Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM) Journal of Clinical Oncology. ,vol. 22, pp. 7528- 7528 ,(2004) , 10.1200/JCO.2004.22.90140.7528
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Ken Wyman, Michael B. Atkins, Victor Prieto, Omar Eton, David F. McDermott, Francie Hubbard, Christine Byrnes, Kathleen Sanders, Jeffrey A. Sosman, Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. ,vol. 106, pp. 2005- 2011 ,(2006) , 10.1002/CNCR.21834
John B. Alexis, Antonio E. Martinez, Jose Lutzky, An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Research. ,vol. 15, pp. 283- 285 ,(2005) , 10.1097/00008390-200508000-00008
S Ugurel, R Hildenbrand, A Zimpfer, P La Rosée, P Paschka, A Sucker, P Keikavoussi, J C Becker, W Rittgen, A Hochhaus, D Schadendorf, Lack of clinical efficacy of imatinib in metastatic melanoma British Journal of Cancer. ,vol. 92, pp. 1398- 1405 ,(2005) , 10.1038/SJ.BJC.6602529
Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Charles D. Blanke, Margaret von Mehren, Heikki Joensuu, Laura S. McGreevey, Chang-Jie Chen, Annick D. Van den Abbeele, Brian J. Druker, Beate Kiese, Burton Eisenberg, Peter J. Roberts, Samuel Singer, Christopher D.M. Fletcher, Sandra Silberman, Sasa Dimitrijevic, Jonathan A. Fletcher, Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Journal of Clinical Oncology. ,vol. 21, pp. 4342- 4349 ,(2003) , 10.1200/JCO.2003.04.190
John A. Curtin, Klaus Busam, Daniel Pinkel, Boris C. Bastian, Somatic Activation of KIT in Distinct Subtypes of Melanoma Journal of Clinical Oncology. ,vol. 24, pp. 4340- 4346 ,(2006) , 10.1200/JCO.2006.06.2984
A. Baldi, R. Dangelillo, B. Vincenzi, D. Santini, L. Trodella, A. La Cesa, E. Finolezzi, N. Onori, G. Tonini, Prevention of radiotherapy-induced emesis. Journal of Experimental & Clinical Cancer Research. ,vol. 22, pp. 17- 20 ,(2003)
T. Facon, J. Mary, J. Harousseau, F. Huguet, C. Berthou, B. Grosbois, B. Anglaret, A. Azzedine, P. Rodon, A. Peny, Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma Journal of Clinical Oncology. ,vol. 24, pp. 1- 1 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.1